Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
Sun Pharma Advanced Research faces critical compliance exposure under SEBI BRSR Core Expansion, with a maximum compliance risk score of 10.0/10 creating potential enforcement action and delisting risk if mandatory disclosures are not fully met. The company's greatest financial vulnerability is EPR (Extended Producer Responsibility) exposure rated 6.5/10—currently unquantified but likely material given the pharma R&D sector's chemical waste streams and packaging obligations under India's waste management rules. With ₹71.8 crore revenue, even modest EPR compliance infrastructure costs (estimated ₹0.5–2 crore range for pharma waste management systems) represent 0.7–2.8% revenue impact. Immediate priority: formalize Scope 1/2 emissions tracking and EPR applicability assessment to mitigate regulatory penalties and avoid SEBI enforcement action.
Source: Sun Pharma Advanced Research Company Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.